Brief: Acer Therapeutics And Relief Therapeutics: China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent

MindMaze Therapeutics Holding SA

08/07/2022 06:06

July 8 (Reuters) - RELIEF THERAPEUTICS HOLDING SA  RLFB.S :
    * ACER THERAPEUTICS AND RELIEF THERAPEUTICS ANNOUNCE THAT
THE
CHINA NATIONAL INTELLECTUAL PROPERTY ADMINISTRATION (CNIPA)
ISSUED UTILITY MODEL PATENT 11,202,767 COVERING ACER-001 DOSAGE
FORM
    * ACER THERAPEUTICS INC. (NASDAQ: ACER) (ACER) AND ITS
COLLABORATION PARTNER, RELIEF THERAPEUTICS HOLDING SA (SIX: RLF,
OTCQB: RLFTF, RLFTY) (RELIEF), TODAY ANNOUNCED THAT CHINA
NATIONAL INTELLECTUAL PROPERTY ADMINISTRATION ("CNIPA") ISSUED
ELECTRONIC PATENT CERTIFICATE ZL202122004991.9 ON MAY 24, 2022,
FOR UTILITY MODEL DIRECTED TO ACER-001 (SODIUM PHENYLBUTYRATE)
    * SPECIFICALLY, NEWLY ISSUED PATENT COVERS DOSAGE FORM
CLAIMS
RELATED TO ACER-001'S POLYMER COATED FORMULATION FOR ORAL
ADMINISTRATION AS A POTENTIAL TREATMENT FOR UREA CYCLE DISORDERS
("UCDS") AND MAPLE SYRUP URINE DISEASE ("MSUD")
    * NEWLY ISSUED PATENT HAS AN EXPIRATION DATE OF AUGUST 24,
2031

Source text for Eikon:  ID:nEQ8T26FHa 
Further company coverage:  RLFB.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))